256 related articles for article (PubMed ID: 26202595)
1. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Pietanza MC; Waqar SN; Krug LM; Dowlati A; Hann CL; Chiappori A; Owonikoko TK; Woo KM; Cardnell RJ; Fujimoto J; Long L; Diao L; Wang J; Bensman Y; Hurtado B; de Groot P; Sulman EP; Wistuba II; Chen A; Fleisher M; Heymach JV; Kris MG; Rudin CM; Byers LA
J Clin Oncol; 2018 Aug; 36(23):2386-2394. PubMed ID: 29906251
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; Mohile N; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M
J Neurooncol; 2016 Jan; 126(2):309-16. PubMed ID: 26508094
[TBL] [Abstract][Full Text] [Related]
5. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
6. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S
Ann Oncol; 2018 Jan; 29(1):154-161. PubMed ID: 29045554
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
[TBL] [Abstract][Full Text] [Related]
10. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M; Carducci MA; Slovin S; Cetnar J; Qian J; McKeegan EM; Refici-Buhr M; Chyla B; Shepherd SP; Giranda VL; Alumkal JJ
Invest New Drugs; 2014 Oct; 32(5):904-12. PubMed ID: 24764124
[TBL] [Abstract][Full Text] [Related]
15. [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Conill C; Fernández-Ibiza J; Malvehy J; Puig S; Sánchez M; Castel T
Med Clin (Barc); 2004 Mar; 122(11):413-5. PubMed ID: 15066248
[TBL] [Abstract][Full Text] [Related]
16. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.
Chabot P; Hsia TC; Ryu JS; Gorbunova V; Belda-Iniesta C; Ball D; Kio E; Mehta M; Papp K; Qin Q; Qian J; Holen KD; Giranda V; Suh JH
J Neurooncol; 2017 Jan; 131(1):105-115. PubMed ID: 27655223
[TBL] [Abstract][Full Text] [Related]
17. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA
N Engl J Med; 2019 Dec; 381(25):2403-2415. PubMed ID: 31562800
[TBL] [Abstract][Full Text] [Related]
18. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Palma JP; Wang YC; Rodriguez LE; Montgomery D; Ellis PA; Bukofzer G; Niquette A; Liu X; Shi Y; Lasko L; Zhu GD; Penning TD; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
Clin Cancer Res; 2009 Dec; 15(23):7277-90. PubMed ID: 19934293
[TBL] [Abstract][Full Text] [Related]
19. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
